Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-joint-research-sets-a-new-global-direction-for-lung-cancer-treatment-molecular-targeted-therapy-proved-more-effective-in-treating-patients-with-alk-positive-lung-cancer
https://www.med.cuhk.edu.hk/press-releases/cuhk-joint-research-sets-a-new-global-direction-for-lung-cancer-treatment-molecular-targeted-therapy-proved-more-effective-in-treating-patients-with-alk-positive-lung-cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

The Faculty of Medicine of The Chinese University of Hong Kong (CUHK) has proved that molecular targeted therapy is superior to standard first-line chemotherapy in ALK-positive lung cancer patients.  From now on, in addition to the testing of epidermal growth factor receptor (EGFR), patients with lung adenocarcinoma will also undergo EML4-ALK gene mutation (an abnormal gene fusion) test before considering the preferred cancer treatment, whether it should be molecular targeted therapy or standard chemotherapy. This personalized therapy based on human genomic information has set a new global direction for lung cancer treatment. The findings have been published in the latest issue of The New England Journal of Medicine. 

 

Lung cancer is the leading cause of cancer deaths worldwide, accounting for 1.6 million deaths every year. In Hong Kong, there are around 4,000 new cases of lung cancer annually. Among which, 70% of patients suffer from lung adenocarcinoma and many of them are female and non-smokers. 

 

It was found that EML4-ALK mutation is a driver oncogene leading to lung adenocarcinoma in 2007, which is present in 3% to 5% of non-small-cell lung cancer cases. Professor Tony Mok from the Department of Clinical Oncology at CUHK and Dr. Benjamin Solomon, an Australian expert, jointly conducted an international research from May 2011 to July 2013. In the study, 343 patients with ALK-positive lung adenocarcinoma from 27 countries were randomly divided into 2 groups, receiving molecular targeted therapy and standard chemotherapy respectively. The results revealed that molecular targeted therapy was more effective with more than 10 months of progression-free survival, 50% higher than standard chemotherapy. In addition, the probability of 1-year survival was over 80% with molecular targeted therapy. As compared to chemotherapy, it also had fewer side effects and was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life. 

 

 Molecular Targeted Therapy(172 ppx)Standard Chemotherapy (171 ppx)
Progression-free survival (Median)10.9 months7.0 months
Objective response74%45%
Probability of 1-year survival84%79%

 

Professor Tony Mok, Li Shu Fan Medical Foundation Professor of Clinical Oncology from Department of Clinical Oncology at CUHK described the research as ground breaking which set a new global direction for lung cancer treatment.  He said, “From now on, patients with lung adenocarcinoma should undergo both EGFR and EML4-ALK gene mutation test before any treatments. If one of the tests shows positive result, molecular targeted therapy will be more effective than the standard chemotherapy.” 

 

Professor Mok added that physicians are now able to provide patients with tailor-made therapy by targeting the cancer cause based on genomic information. This personalized therapy approach will bring greater hope to advanced lung cancer patients. 

 

This remarkable research result by Professor Mok marks another milestone in lung cancer treatment after his landmark study in 2009, which had established the role of first-line treatment in patients with EGFR mutation. These two studies not only bring the personalized medicine development of lung cancer into a new stage, but also establish the international leadership of Asian scholars in research and treatment of Clinical Oncology.

 

Prof. Tony Mok, Professor, Department of Clinical Oncology at CUHK

Prof. Tony MOK, Professor, Department of Clinical Oncology at CUHK shares the research findings that molecular targeted therapy is superior to standard first-line chemotherapy in treating ALK-positive lung cancer patients.

The ground breaking research by Prof., Professor, Department of Clinical Oncology at CUHK

The ground breaking research by Prof. Tony Mok, Department of Clinical Oncology at CUHK, has set a new global direction for lung cancer treatment: patients with lung adenocarcinoma are recommended to undergo both EGFR and EML4-ALK gene mutation tests before considering the treatment approach.

Ms. Chan, an ALK-positive lung cancer patient

Ms. Chan, an ALK-positive lung cancer patient (2nd right), has received molecular targeted therapy for two years. She is satisfied with the treatment which has significantly reduced the tumor size. From left are Prof. Tony Mok, Li Shu Fan Professor of Clinical Oncology; Prof. Anthony Chan, Li Shu Fan Professor of Clinical Oncology and Chairman of Department of Clinical Oncology; and Dr. Lam Kwok Chi, Clinical Assistant Professor (Honorary), Department of Clinical Oncology, CUHK.

 

More Press Releases

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
Factsheet on Personalised Medicine (Only available in Chinese Version)

Factsheet on Personalised Medicine (Only available in Chinese Version)

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium
CUHK Study Finds Earlier Endoscopy Did Not Reduce Mortality and Risk of Further Bleeding in Acute Upper Gastrointestinal Bleeding Patients

CUHK Study Finds Earlier Endoscopy Did Not Reduce Mortality and Risk of Further Bleeding in Acute Upper Gastrointestinal Bleeding Patients

Research
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
CUHK Jointly Discovers New Therapeutic Solution for Minor Stroke in Global Study with over 30 Countries

CUHK Jointly Discovers New Therapeutic Solution for Minor Stroke in Global Study with over 30 Countries

Research
CUHK Sees Early Evaluation of TIA Patients Reduce Rate of Stroke by 70% in a Global Study of 21 Countries

CUHK Sees Early Evaluation of TIA Patients Reduce Rate of Stroke by 70% in a Global Study of 21 Countries

Research
CUHK Professor Dennis Lo Received International Honour for Pioneering Research in Personalized Medicine

CUHK Professor Dennis Lo Received International Honour for Pioneering Research in Personalized Medicine

Awards and honors
CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

Clinical service

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.